Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?. // Clinical Microbiology and Infection. – URL: https://www.sciencedirect.com/science/article/pii/S1198743X26006488?dgcid=rss_sd_all
Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?. Clinical Microbiology and Infection. https://www.sciencedirect.com/science/article/pii/S1198743X26006488?dgcid=rss_sd_all
“Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?.” Clinical Microbiology and Infection.
@article{article40964,
title = {Which trial do we need? RSV booster vaccination in immunocompromised patients: Immunogenicity, safety and efficacy of booster vaccination strategies – Boost or bypass?},
journal = {Clinical Microbiology and Infection},
url = {https://www.sciencedirect.com/science/article/pii/S1198743X26006488?dgcid=rss_sd_all}
}